• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经肝内侧支循环途径行肝静脉再通术治疗布加综合征的可行性和长期疗效。

Feasibility and long-term outcomes of hepatic vein recanalization in Budd-Chiari syndrome through intrahepatic collateral pathways.

机构信息

Department of Interventional Radiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

出版信息

Eur J Gastroenterol Hepatol. 2024 Oct 1;36(10):1230-1237. doi: 10.1097/MEG.0000000000002822. Epub 2024 Jul 15.

DOI:10.1097/MEG.0000000000002822
PMID:39012650
Abstract

BACKGROUND AND AIMS

To investigate the feasibility and long-term outcomes of hepatic vein (HV) recanalization using intrahepatic collateral pathways in patients with Budd-Chiari syndrome (BCS) with HV obstruction.

METHODS

Clinical data of 29 BCS patients with HV obstruction and intrahepatic collateral pathways were reviewed. All patients underwent HV recanalization through the intrahepatic collaterals. Follow-up was performed at 1, 3, 6, and 12 months after treatment and annually thereafter. Cumulative patency and survival rates were assessed using Kaplan-Meier curves. The independent predictors of patency were determined using a Cox regression model.

RESULTS

HV recanalization was successful in 28 of the 29 patients (96.6%), with no complications. Of the 28 cases, simultaneous recanalization of the accessory HV and right HV was achieved in 11 patients, accessory HV and middle HV in six, accessory HV and left HV in three, right HV and middle HV in five, and left HV and middle HV in three. Twenty-eight patients were followed from 4 to 87 (mean, 53.6 ± 26.7) months after treatment, and six patients developed reocclusion. The overall cumulative 1-, 3-, 5-, and 7-year primary HV patency rates were 96.3, 82.9, 74.6, and 59.7%, respectively. The cumulative 1-, 3-, 5-, and 7-year survival rates were 100, 95.8, 95.8, and 86.3%, respectively.

CONCLUSION

Interventional treatment of HV obstruction in BCS patients through intrahepatic collateral approaches is well tolerated and feasible and can result in excellent long-term patency and survival rates.

摘要

背景与目的

探讨经肝内侧支途径治疗肝静脉(HV)阻塞型布加综合征(BCS)患者的可行性及长期疗效。

方法

回顾性分析 29 例 HV 阻塞伴肝内侧支的 BCS 患者的临床资料,所有患者均经肝内侧支途径行 HV 再通术。治疗后 1、3、6、12 个月及此后每年进行随访,采用 Kaplan-Meier 曲线评估累积通畅率和生存率,采用 Cox 回归模型分析影响通畅率的独立预测因素。

结果

29 例患者中 28 例(96.6%)HV 再通成功,无并发症发生。28 例患者中,11 例同时再通副肝静脉和右肝静脉,6 例再通副肝静脉和中肝静脉,3 例再通副肝静脉和左肝静脉,5 例再通右肝静脉和中肝静脉,3 例再通左肝静脉和中肝静脉。28 例患者的随访时间为 4~87 个月(平均 53.6±26.7 个月),6 例患者发生再闭塞。总的 1、3、5、7 年 HV 通畅率分别为 96.3%、82.9%、74.6%和 59.7%,1、3、5、7 年生存率分别为 100%、95.8%、95.8%和 86.3%。

结论

经肝内侧支途径治疗 HV 阻塞型 BCS 患者是一种安全、可行的方法,可获得良好的长期通畅率和生存率。

相似文献

1
Feasibility and long-term outcomes of hepatic vein recanalization in Budd-Chiari syndrome through intrahepatic collateral pathways.经肝内侧支循环途径行肝静脉再通术治疗布加综合征的可行性和长期疗效。
Eur J Gastroenterol Hepatol. 2024 Oct 1;36(10):1230-1237. doi: 10.1097/MEG.0000000000002822. Epub 2024 Jul 15.
2
Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.经皮再通治疗肝静脉型布加综合征:长期通畅率和生存率。
Hepatol Int. 2016 Mar;10(2):363-9. doi: 10.1007/s12072-015-9676-3. Epub 2015 Oct 23.
3
Radical surgical treatment of Budd-Chiari syndrome through entire exposure of hepatic inferior vena cava.经肝下腔静脉全程显露行布加综合征根治性手术
J Vasc Surg Venous Lymphat Disord. 2019 Jan;7(1):74-81. doi: 10.1016/j.jvsv.2018.02.007. Epub 2018 Oct 16.
4
Recanalization of accessory hepatic vein for hepatic vein-type Budd-Chiari syndrome.开通副肝静脉治疗肝静脉型布加综合征。
Abdom Radiol (NY). 2021 Jul;46(7):3456-3463. doi: 10.1007/s00261-021-02977-1. Epub 2021 Feb 25.
5
Percutaneous recanalization for combined-type Budd-Chiari syndrome: strategy and long-term outcome.经皮再通术治疗混合型布加综合征:策略与长期疗效
Abdom Imaging. 2015 Oct;40(8):3240-7. doi: 10.1007/s00261-015-0496-7.
6
Percutaneous recanalization in hepatic vein-type Budd-Chiari syndrome: hepatic or accessory hepatic vein.经皮肝静脉型布加综合征再通术:肝静脉或副肝静脉。
Minim Invasive Ther Allied Technol. 2023 Feb;32(1):18-23. doi: 10.1080/13645706.2022.2145568. Epub 2022 Nov 18.
7
Feasibility and midterm outcomes of percutaneous transhepatic balloon angioplasty for symptomatic Budd-Chiari syndrome secondary to hepatic venous obstruction.经皮经肝球囊血管成形术治疗肝静脉阻塞所致症状性布加综合征的可行性及中期疗效
J Vasc Surg. 2009 Nov;50(5):1079-84. doi: 10.1016/j.jvs.2009.06.049. Epub 2009 Aug 22.
8
Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.经血管内治疗肝静脉型布加综合征:疗效和长期结果。
Radiol Med. 2018 Oct;123(10):799-807. doi: 10.1007/s11547-018-0907-2. Epub 2018 May 31.
9
Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome.经皮肝静脉再通术治疗布加综合征的长期疗效。
Liver Int. 2017 Jan;37(1):111-120. doi: 10.1111/liv.13180. Epub 2016 Jul 5.
10
Retrograde puncture assisted hepatic vein recanalization in treating Budd-Chiari syndrome with segmental obstruction of hepatic vein.逆行穿刺辅助肝静脉再通术治疗肝静脉节段性梗阻型布加综合征
Radiol Med. 2015 Dec;120(12):1184-9. doi: 10.1007/s11547-015-0557-6. Epub 2015 Jun 7.